Overview

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This study is being conducted this study to determine whether injections of Xeomin®, a type of botulinum toxin into the glands that produce saliva (one pair just below and in front of the ear and the other just under the jaw line) are safe and effective to treat excessive saliva, or drooling in patients with Parkinson's Disease (PD)/parkinsonism.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Treatments:
incobotulinumtoxinA